More specifically the ASCO abstract that shows a dose limiting toxicity was established and in patients that did not respond to any other treatment it stabilized the disease in almost half (11/26)
Patients exhibited immune cell activation with a stable or decrease in the levels of suppressive immune cells, accompanied by increased immunostimulatory and decreased immunosuppressive cytokines. Stable disease for more than 6 weeks was observed in 8 patients, with 3 maintaining SD for more than 12 weeks.
Conclusions: The recommended phase II dose of entolimod was30 µg/day on days 1, 4, 8, 11. The clinical results corroborated pre-clinical findings and support entolimod’s potential as an immunotherapeutic agent. The safety profile suggests that entolimod can be combined with chemotherapeutic, targeted, or other immunotherapeutic agents. Clinical trial information: NCT01527236.